Cargando…
Metabolic syndrome and cardiovascular morbidity in patients with congenital adrenal hyperplasia
Since the introduction of glucocorticoid (GC) replacement therapy, congenital adrenal hyperplasia (CAH) is no longer a fatal disease. The development of neonatal screening programs and the amelioration of GC treatment strategies have improved significantly life expectancy in CAH patients. Thanks to...
Autores principales: | Barbot, Mattia, Mazzeo, Pierluigi, Lazzara, Martina, Ceccato, Filippo, Scaroni, Carla |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9376294/ https://www.ncbi.nlm.nih.gov/pubmed/35979433 http://dx.doi.org/10.3389/fendo.2022.934675 |
Ejemplares similares
-
The Pathophysiology and Treatment of Hypertension in Patients With Cushing's Syndrome
por: Barbot, Mattia, et al.
Publicado: (2019) -
Diabetes Mellitus Secondary to Cushing’s Disease
por: Barbot, Mattia, et al.
Publicado: (2018) -
Frequently Asked Questions in Patients With Adrenal Insufficiency in the Time of COVID-19
por: Sabbadin, Chiara, et al.
Publicado: (2021) -
Components of Metabolic Syndrome in Youth With Classical Congenital Adrenal Hyperplasia
por: Kim, Mimi S., et al.
Publicado: (2022) -
Consideration on TMPRSS2 and the risk of COVID-19 infection in Cushing’s syndrome
por: Barbot, Mattia, et al.
Publicado: (2020)